

Ajay K Nooka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9175783/publications.pdf>

Version: 2024-02-01

226
papers

7,998
citations

117625

34
h-index

54911

84
g-index

227
all docs

227
docs citations

227
times ranked

8088
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 754-766.	27.0	1,246
2	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
3	Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 826-836.	2.8	527
4	Oral Selinexor + Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
5	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nature Communications</i> , 2018, 9, 5341.	12.8	356
6	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013, 98, 1753-1761.	3.5	300
7	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	27.0	291
8	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
9	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. <i>Haematologica</i> , 2018, 103, 2079-2087.	3.5	225
10	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	1.6	148
11	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	1.6	140
12	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015, 125, 3085-3099.	1.4	136
13	Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. <i>Cancer</i> , 2011, 117, 2530-2540.	4.1	125
14	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	12.8	109
15	Thalidomide in the treatment of patients with hepatocellular carcinoma. <i>Cancer</i> , 2005, 103, 749-755.	4.1	107
16	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. <i>JCI Insight</i> , 2019, 4, .	5.0	107
17	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019, 9, 94.	6.2	104
18	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. <i>Ophthalmology and Therapy</i> , 2020, 9, 889-911.	2.3	101

#	ARTICLE	IF	CITATIONS
19	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019, 125, 2364-2382.	4.1	100
20	A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study. <i>Clinical Cancer Research</i> , 2010, 16, 5079-5086.	7.0	94
21	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM2 study. <i>Cancer</i> , 2021, 127, 4198-4212.	4.1	89
22	Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. <i>Blood</i> , 2017, 129, 1969-1979.	1.4	85
23	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	4.1	83
24	Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. <i>Annals of Oncology</i> , 2013, 24, 441-448.	1.2	79
25	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of retreatment with daratumumab among refractory patients. <i>Cancer</i> , 2019, 125, 2991-3000.	4.1	73
26	Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. <i>Blood</i> , 2017, 129, 3033-3037.	1.4	71
27	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, e183267.	7.1	63
28	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1228.	12.8	62
29	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
30	In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy. <i>Journal of Biological Chemistry</i> , 2015, 290, 14441-14453.	3.4	52
31	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021, 137, 3604-3615.	1.4	44
32	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 116.	6.2	44
33	Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. <i>JCI Insight</i> , 2020, 5, .	5.0	43
34	A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of <i>Clostridium difficile</i> -associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2019, 68, 196-203.	5.8	41
35	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	3.5	41
36	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. <i>Blood Cancer Journal</i> , 2019, 9, 3.	6.2	39

#	ARTICLE	IF	CITATIONS
37	Bortezomib-containing induction regimens in transplant-eligible myeloma patients. <i>Cancer</i> , 2013, 119, 4119-4128.	4.1	36
38	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. <i>Leukemia</i> , 2019, 33, 1291-1296.	7.2	36
39	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019, 125, 416-423.	4.1	36
40	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. <i>Journal of Oncology Practice</i> , 2018, 14, 414-422.	2.5	35
41	High-risk Multiple Myeloma: Definition and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S80-S87.	0.4	34
42	Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 2142-2142.	1.4	34
43	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. <i>Oncotarget</i> , 2016, 7, 59727-59741.	1.8	33
44	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. <i>Cancer</i> , 2010, 116, 3143-3151.	4.1	32
45	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). <i>Blood Cancer Journal</i> , 2021, 11, 103.	6.2	32
46	DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8502-8502.	1.6	32
47	Development of GLUT4-selective antagonists for multiple myeloma therapy. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 573-586.	5.5	31
48	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	1.6	31
49	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	1.3	30
50	Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor. <i>Blood</i> , 2016, 128, 1150-1150.	1.4	30
51	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 852-857.	2.0	29
52	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2018, 124, 4342-4349.	4.1	29
53	Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 896-896.	1.4	29
54	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27

#	ARTICLE	IF	CITATIONS
55	Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare. <i>Blood Cancer Discovery</i> , 2021, 2, 119-124.	5.0	27
56	DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 19-20.	1.4	27
57	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	1.6	26
58	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8536-8536.	1.6	24
59	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021, 17, 1987-2003.	2.4	23
60	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor. <i>Blood</i> , 2019, 134, 3192-3192.	1.4	22
61	Bilateral adrenal hemorrhage: An overlooked cause of hypotension. <i>Journal of Emergency Medicine</i> , 2007, 32, 167-169.	0.7	21
62	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	1.4	21
63	Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients. <i>Blood</i> , 2016, 128, 492-492.	1.4	21
64	Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8013-8013.	1.6	20
65	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. <i>Oncotarget</i> , 2016, 7, 27753-27763.	1.8	19
66	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	1.6	19
67	Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1393-1395.	2.0	18
68	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1609-1618.	2.5	18
69	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016, 17, 769-777.	3.4	17
70	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598.	1.4	17
71	Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. <i>Cancer</i> , 2016, 122, 3207-3214.	4.1	16
72	Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). <i>Blood</i> , 2016, 128, 3307-3307.	1.4	16

#	ARTICLE	IF	CITATIONS
73	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	5.2	16
74	CD86 regulates myeloma cell survival. <i>Blood Advances</i> , 2017, 1, 2307-2319.	5.2	15
75	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	6.2	15
76	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 3178-3189.	7.0	15
77	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	5.0	15
78	An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8002-8002.	1.6	15
79	Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low I \pm 1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. <i>Blood</i> , 2013, 122, 285-285.	1.4	14
80	Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial. <i>Blood</i> , 2014, 124, 32-32.	1.4	14
81	Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. <i>Biologics: Targets and Therapy</i> , 2013, 7, 13.	3.2	13
82	Description of the types and content of phase 1 clinical trial consent conversations in practice. <i>Clinical Trials</i> , 2015, 12, 567-574.	1.6	13
83	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	1.4	13
84	Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma. <i>Blood</i> , 2014, 124, 2139-2139.	1.4	13
85	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8519-8519.	1.6	13
86	New Targets and New Agents in High-Risk Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e431-e441.	3.8	12
87	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	1.4	12
88	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	1.4	12
89	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018, 132, 3282-3282.	1.4	11
90	Myeloma Is Not a Single Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 287-292.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infection Control and Hospital Epidemiology, 2017, 38, 651-657.	1.8	10
92	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Future Oncology, 2018, 14, 3111-3121.	2.4	10
93	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British Journal of Haematology, 2021, 193, 561-569.	2.5	10
94	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. Blood, 2018, 132, 3288-3288.	1.4	10
95	Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e526-e531.	0.4	10
96	The Importance of Complete Response in Outcomes in Myeloma. Cancer Journal (Sudbury, Mass), 2009, 15, 465-472.	2.0	9
97	From Single Nucleotide Polymorphisms to Constant Immunosuppression: Mesenchymal Stem Cell Therapy for Autoimmune Diseases. BioMed Research International, 2013, 2013, 1-8.	1.9	9
98	New Targets and New Agents in High-Risk Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e431-e441.	3.8	9
99	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of Oncology Practice, 2018, 14, 561-564.	2.5	8
100	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncology Practice, 2020, 16, e1169-e1180.	2.9	8
101	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. Blood, 2013, 122, 3135-3135.	1.4	8
102	Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.. Journal of Clinical Oncology, 2022, 40, 8018-8018.	1.6	8
103	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leukemia and Lymphoma, 2015, 56, 383-389.	1.3	7
104	Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer Journal (Sudbury, Mass), 2019, 25, 19-31.	2.0	7
105	Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood Cancer Journal, 2020, 10, 125.	6.2	7
106	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American Journal of Hematology, 2021, 96, E68-E71.	4.1	7
107	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. British Journal of Haematology, 2021, 194, 784-788.	2.5	7
108	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). Blood, 2011, 118, 775-775.	1.4	7

#	ARTICLE	IF	CITATIONS
109	Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study. <i>Blood</i> , 2012, 120, 336-336.	1.4	7
110	DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 897-897.	1.4	7
111	Plerixafor in combination with granulocyte "colony" stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015, 55, 2351-2357.	1.6	6
112	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S249-S250.	0.4	6
113	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	1.3	6
114	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 697-706.	2.2	6
115	Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor. <i>Blood</i> , 2018, 132, 3270-3270.	1.4	6
116	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. <i>Blood</i> , 2018, 132, 952-952.	1.4	6
117	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 26-27.	1.4	6
118	Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4241-4241.	1.4	6
119	Sequential or combination therapy for multiple myeloma. <i>Expert Review of Hematology</i> , 2012, 5, 533-545.	2.2	5
120	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 797-803.	0.4	5
121	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 149.	6.2	5
122	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. <i>Blood</i> , 2011, 118, 3994-3994.	1.4	5
123	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	1.2	5
124	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. <i>Blood Cancer Journal</i> , 2022, 12, 63.	6.2	5
125	Supportive Therapies in Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 971-979.	4.9	4
126	Improving Induction Therapy in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 119-128.	2.3	4

#	ARTICLE	IF	CITATIONS
127	Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease. <i>Current Drug Delivery</i> , 2012, 9, 41-51.	1.6	4
128	Novel combination approaches for myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 286-293.	2.5	4
129	Is Maintenance Therapy for Everyone?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S139-S144.	0.4	4
130	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. <i>Cancer</i> , 2018, 124, 4358-4365.	4.1	4
131	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019, 125, 185-193.	4.1	4
132	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. <i>Blood</i> , 2011, 118, 1855-1855.	1.4	4
133	Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea. <i>Blood</i> , 2014, 124, 5779-5779.	1.4	4
134	Optimal Dosing of Melphalan As High-Dose Therapy Before Autologous Hematopoietic Stem Cell Transplantation in Myeloma Patients With Solitary Kidney: A Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e59-e63.	0.4	3
135	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016, 06, .	0.3	3
136	RVD is a Superior Induction Regimen Compared to VCD Among Transplant-Eligible Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e137-e138.	0.4	3
137	MM-350: Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S308-S309.	0.4	3
138	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 5647-5647.	1.4	3
139	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. <i>Blood</i> , 2019, 134, 1872-1872.	1.4	3
140	Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry. <i>Blood</i> , 2012, 120, 2072-2072.	1.4	3
141	Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2014, 124, 4737-4737.	1.4	3
142	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8584-8584.	1.6	3
143	Safety and efficacy of daratumumab-based regimens in elderly (>=75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8033-8033.	1.6	3
144	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. <i>Southern Medical Journal</i> , 2014, 107, 497-500.	0.7	3

#	ARTICLE	IF	CITATIONS
145	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. <i>Blood</i> , 2018, 132, 405-405.	1.4	3
146	Carfilzomib 56 mg/m ² twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DvD): a matching-adjusted indirect treatment comparison. <i>Leukemia and Lymphoma</i> , 2022, 63, 1887-1896.	1.3	3
147	β ² adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. <i>Haematologica</i> , 2022, 107, 2226-2231.	3.5	3
148	Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e118-e119.	0.4	2
149	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021, 2, 375-384.	1.0	2
150	“I took the road less traveled, and that has made all the difference.” Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2021, 127, 4133-4136.	4.1	2
151	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. <i>Blood</i> , 2018, 132, 2655-2655.	1.4	2
152	Safety and Efficacy of Evomela, in Myeloma Autotransplants. <i>Blood</i> , 2018, 132, 3446-3446.	1.4	2
153	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018, 132, 3294-3294.	1.4	2
154	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1924-1924.	1.4	2
155	Efficacy Of ABT-199 In Multiple Myeloma. <i>Blood</i> , 2013, 122, 4453-4453.	1.4	2
156	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2015, 126, 4246-4246.	1.4	2
157	Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). <i>Blood</i> , 2015, 126, 5344-5344.	1.4	2
158	B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma. <i>Blood</i> , 2016, 128, 2108-2108.	1.4	2
159	Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2016, 128, 2124-2124.	1.4	2
160	Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT) Tj ETQq0 0 Q.rgBT /Overlock 10 T		
161	P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for 12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S149-S150.	0.4	2
162	Moving Toward a Cure for Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 1-12.	3.8	2

#	ARTICLE	IF	CITATIONS
163	Predictors of survival outcomes in phase I relapsed or refractory multiple myeloma patients. <i>Cancer</i> , 2015, 121, 853-862.	4.1	1
164	Death by a thousand cuts: the slow demise of chemotherapy. <i>Cancer</i> , 2016, 122, 1971-1973.	4.1	1
165	TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. <i>Blood Advances</i> , 2017, 1, 1848-1853.	5.2	1
166	MM-219: Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S301-S302.	0.4	1
167	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018, 132, 3241-3241.	1.4	1
168	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. <i>Blood</i> , 2018, 132, 1884-1884.	1.4	1
169	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2157-2157.	1.4	1
170	Osteonecrosis of the Jaw or Maxilla after Intravenous Bisphosphonates for Multiple Myeloma and Breast Cancer: Long-Term Follow-Up Shows a Slow Rate of Healing.. <i>Blood</i> , 2006, 108, 5121-5121.	1.4	1
171	Impact of Body Mass Index (BMI) On Overall Survival in Myeloma. <i>Blood</i> , 2012, 120, 4289-4289.	1.4	1
172	Vorinostat, Bortezomib, Cyclophosphamide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 5773-5773.	1.4	1
173	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). <i>Blood</i> , 2016, 128, 3250-3250.	1.4	1
174	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8540-8540.	1.6	1
175	Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.. <i>Blood</i> , 2009, 114, 3888-3888.	1.4	1
176	Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States. <i>Blood</i> , 2015, 126, 4508-4508.	1.4	1
177	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018, 132, 5911-5911.	1.4	1
178	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) <i>TJ ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>		
179	P-170: Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S129.	0.4	1
180	Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DvD); A Matching-Adjusted Indirect Treatment Comparison. <i>Blood</i> , 2020, 136, 8-9.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. <i>Pharmacotherapy</i> , 2022, 42, 233-240.	2.6	1
182	Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S191.	2.0	0
183	Simplified Technique for Administration of High Dose Melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S291-S292.	2.0	0
184	Meningeal Myelomatosis. <i>Journal of Oncology Practice</i> , 2016, 12, 187-188.	2.5	0
185	The Role of Consolidation and Maintenance in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S143.	0.4	0
186	Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e68-e69.	0.4	0
187	Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e133.	0.4	0
188	32 Laboratory Evaluation for Therapy-Related Myeloid Neoplasia-Associated Changes After Autotransplant for Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2018, 149, S180-S180.	0.7	0
189	Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S137-S138.	2.0	0
190	How Does Genetics and MRD Impact Treatment or Doesn't It?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S69-S72.	0.4	0
191	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S250-S251.	0.4	0
192	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) <i>J Clin Oncol</i> 2019; 37(10):1071-1079.	0.0	0
193	Maintenance Strategies for Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 231-238.	2.0	0
194	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials. <i>Blood</i> , 2011, 118, 3954-3954.	1.4	0
195	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. <i>Blood</i> , 2011, 118, 1959-1959.	1.4	0
196	Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status. <i>Blood</i> , 2012, 120, 4713-4713.	1.4	0
197	Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins. <i>Blood</i> , 2012, 120, 4024-4024.	1.4	0
198	Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 2006-2006.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.. Journal of Clinical Oncology, 2013, 31, 7035-7035.	1.6	0
200	Access To Therapeutic Surgical Procedures For Pathologic Fractures In Multiple Myeloma Patients: Analysis of Nationwide Inpatient Sample (NIS). Blood, 2013, 122, 1709-1709.	1.4	0
201	Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). Blood, 2013, 122, 5606-5606.	1.4	0
202	Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. Blood, 2013, 122, 5582-5582.	1.4	0
203	P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. Blood, 2013, 122, 1929-1929.	1.4	0
204	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). Blood, 2013, 122, 3148-3148.	1.4	0
205	Dual Inhibition Of Mcl-1 By The Combination Of Carfilzomib and TG02 In Multiple Myeloma. Blood, 2013, 122, 3171-3171.	1.4	0
206	Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. Blood, 2013, 122, 1856-1856.	1.4	0
207	Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant. Blood, 2014, 124, 3973-3973.	1.4	0
208	Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma. Blood, 2014, 124, 3447-3447.	1.4	0
209	Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies. Blood, 2014, 124, 2525-2525.	1.4	0
210	Risk Factors for Development of Myeloma: Role of Smoking and Alcohol. Blood, 2014, 124, 2604-2604.	1.4	0
211	Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. Blood, 2014, 124, 4726-4726.	1.4	0
212	Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States. Blood, 2015, 126, 5629-5629.	1.4	0
213	Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT). Blood, 2015, 126, 4202-4202.	1.4	0
214	The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality. Blood, 2015, 126, 3325-3325.	1.4	0
215	Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant. Blood, 2016, 128, 4524-4524.	1.4	0
216	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	1.4	0

#	ARTICLE	IF	CITATIONS
217	The Role of Proteasome Activator PA28 [±] in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	1.4	0
218	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 5	1.4	0
219	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. American Journal of Cancer Research, 2021, 11, 3285-3293.	1.4	0
220	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. Blood, 2021, 138, 1616-1616.	1.4	0
221	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	1.4	0
222	Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The Piper Study. Blood, 2021, 138, 1077-1077.	1.4	0
223	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. Blood, 2021, 138, 1611-1611.	1.4	0
224	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 r gBT /Overlock 10 Tf 5	1.4	0
225	Role of clonoSEQ [®] , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. Blood, 2020, 136, 50-51.	1.4	0
226	P-208: Ongoing trials investigating in-class transition (iCT) from parenteral to oral proteasome inhibitor (PI)-based treatment with ixazomib in multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S153.	0.4	0